| Description | Ogalvibart (C-135-LS), a humanized anti-SARS-CoV-2 IgG1 type monoclonal antibody, specifically targets and binds to the spike (S) glycoprotein receptor-binding domain (RBD) of the SARS-CoV-2 virus. When combined with C144LS in a 1:1 ratio, Ogalvibart demonstrates significant preventive activity and effectively prevents the progression of COVID-19 in a rhesus monkey disease model [1]. |
| molecular weight | N/A |
| CAS | 2599039-60-6 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 years |